Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | G6PD | P11413 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864274 | 0.88 | PDE5A (0.43) | TDP1KAT2BMEN1KMT2AALDH1A1 | |
| SCHEMBL28899217 | 0.85 | MAPT (0.52) | CNR2KAT2BMEN1KMT2A | |
| SCHEMBL5864200 | 0.83 | CFTR (0.48) | TDP1G6PDTLR9ALDH1A1 | |
| SCHEMBL9874375 | 0.83 | GLS (0.50) | KAT2BMEN1KMT2AG6PDTLR9 | |
| SCHEMBL20775125 | 0.83 | RECQL (0.57) | ACHECNR2CNR1KAT2B | |
| SCHEMBL1728790 | 0.81 | GLS (0.64) | ACHECNR2CNR1KAT2BALDH1A1 | |
| SCHEMBL5863967 | 0.80 | TDP1 (0.56) | TDP1ACHECNR2CNR1DHFR | |
| SCHEMBL14966684 | 0.79 | GLS (0.45) | KAT2BMEN1KMT2AG6PDTLR9 | |
| SCHEMBL29703247 | 0.78 | TDP1 (0.72) | TDP1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL9027681 | 0.78 | TDP1 (0.72) | TDP1MEN1KMT2AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | TDP1 3540/4885ACHE 2005/4885CNR2 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.